Tumor regression grades, K-RAS mutational profile and c-MET in colorectal liver metastases

Pathology Research and Practice

Volumn 213, Issue 8, 2017, Pages 1002-1009

  Lorenzon, Laura ^a   Ricca, Luana ^a,b   Pilozzi, Emanuela ^a   Lemoine, Antoinette ^b,c   Riggio, Valentina ^a   Giudice, Maria Teresa ^a   Mallel, Giuseppe ^a   Fochetti, Flavio ^a   Balducci, Genoveffa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HÔPITAL PAUL BROUSSE   (France)

^c Universite Paris Sud   (France)

Author keywords

C MET; Colorectal cancer; K RAS; Liver metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; SCATTER FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MET PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CELL VIABILITY; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG RESPONSE; FEMALE; FIBROSIS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOADJUVANT THERAPY; ONCOGENE K RAS; PROTEIN EXPRESSION; SURVIVAL ANALYSIS; TUMOR REGRESSION; ADENOCARCINOMA; ADULT; BIOSYNTHESIS; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; SECONDARY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; FIBROSIS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85019703902     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2017.04.013     Document Type: Article

References (33)

1. Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics. CA Cancer J. Clin. 64 (2014), 9–29.
2. Kemeny, N., Management of Liver Metastases from Colorectal Cancer, 20, 2006, Oncology (Williston Park), 1161–1176 (1179).
3. Lorenzon, L., Pilozzi, E., La Torre, M., et al. Impact and prognostic implications of colon cancers stage II sub-classification through the years. Int. J. Colorectal Dis. 27 (2012), 1311–1318.
4. Kopetz, S., Chang, G.J., Overman, M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 27 (2009), 3677–3683.
5. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. New guidelines to evaluate the response to treatment in solid tumours European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000), 205–216.
6. Rubbia-Brandt, L., Giostra, E., Brezault, C., et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann. Oncol. 18 (2007), 299–304.
7. Viganò, L., Capussotti, L., De Rosa, G., et al. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann. Surg. 258 (2013), 731–740.
8. Blazer, D.G. 3rd, Kishi, Y., Maru, D.M., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J. Clin. Oncol. 26 (2008), 5344–5351.
9. Vauthey, J.N., Zimmitti, G., Kopetz, S.E., et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann. Surg. 258 (2013), 619–627.
10. Gao, H., Guan, M., Sun, Z., Bai, C., High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis. Tumour Biol. 36 (2015), 515–520.
11. Garouniatis, A., Zizi-Sermpetzoglou, A., Rizos, S., et al. Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis?correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met. Tumour Biol. 34 (2013), 2109–2117.
12. Gherardi, E., Birchmeier, W., Birchmeier, C., Vande Woude, G., Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12 (2012), 89–103.
13. Garouniatis, A., Zizi-Sermpetzoglou, A., Rizos, S., et al. FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int. J. Colorectal Dis. 28 (2013), 9–18.
14. www.oncoguida.it.
15. Schomll, H.J., van Cutsem, E., Stein, A., et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann. Oncol. 23 (2012), 2479–2516.
16. www.nccn.rg.
17. Sjo, O.H., Merok, M.A., Svindland, A., Nesbakken, A., Prognostic impact of lymph node harvest and lymph node ratio in patients with colon cancer. Dis. Colon. Rectum, 55, 2012 e15.
18. Ferri, M., Lorenzon, L., Onelli, M.R., et al. Lymph node ratio is a stronger prognostic factor than microsatellite instability in colorectal cancer patients: results from a 7 years follow-up study. Int. J. Surg. 11 (2013), 1016–1021.
19. Mazieres, J., Brugger, W., Cappuzzo, F., et al. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer 82 (2013), 231–237.
20. Pietrantonio, F., Orlandi, A., Inno, A., et al. Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: pitfalls and helpful tricks in a review for clinicians. Crit. Rev. Oncol. Hematol. 95 (2015), 272–281.
21. Chang, H.H., Leeper, W.R., Chan, G., et al. Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am. J. Surg. Pathol. 36 (2012), 570–576.
22. Dede, K., Salamon, F., Landherr, R., et al. Pathologic assessment of response to chemotherapy in colorectal cancer liver metastases after hepatic resection: which method to use?. Pathol. Oncol. Res. 21 (2015), 173–179.
23. Aloysius, M.M., Zaitoun, A.M., Beckingham, I.J., et al. The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. Virchows Arch. 451 (2007), 943–948.
24. Sebagh, M., Allard, M.A., Cunha, A.S., et al. A proposed new method for assessing the pathological response to chemotherapy in resected colorectal liver metastases. Br. J. Cancer 111 (2014), 470–476.
25. Pietrantonio, F., Mazzaferro, V., Miceli, R., et al. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Med. Oncol., 32, 2015, 182.
26. Gonsalves, W.I., Mahoney, M.R., Sargent, D.J., et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J. Natl. Cancer Inst., 106(7), 2014, 10.1093/jnci/dju106.
27. El-Deiry, W.S., Vijayvergia, N., Xiu, J., et al. Molecular profiling of 6, 892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol. Ther. 16 (2015), 1726–1737.
28. Takeuchi, H., Bilchik, A., Saha, S., et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin. Cancer Res. 9 (2003), 1480–1488.
29. Shoji, H., Yamada, Y., Taniguchi, H., et al. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Sci. 105 (2014), 1002–1007.
30. Voutsina, A., Tzardi, M., Kalikaki, A., et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod. Pathol. 26 (2013), 302–313.
31. Isaksson-Mettavainio, M., Van Guelpen, B., Oberg, A., et al. C-Met expression in primary tumors and their corresponding distant metastases. Mol. Med. Rep. 1 (2008), 787–790.
32. Matsui, S., Osada, S., Tomita, H., et al. Clinical significance of aggressive hepatectomy for colorectal liver metastasis, evaluated from the HGF ⁄ c-Met pathway. Int. J. Oncol. 37 (2010), 289–297.
33. Bradley, C.A., Dunne, P.D., Bingham, V., et al. Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. Oncotarget 7 (2016), 78932–78945.